NO20070176L - Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav - Google Patents
Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse deravInfo
- Publication number
- NO20070176L NO20070176L NO20070176A NO20070176A NO20070176L NO 20070176 L NO20070176 L NO 20070176L NO 20070176 A NO20070176 A NO 20070176A NO 20070176 A NO20070176 A NO 20070176A NO 20070176 L NO20070176 L NO 20070176L
- Authority
- NO
- Norway
- Prior art keywords
- pyrazoles
- compounds
- drugs containing
- glycoside derivatives
- new fluorine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229910052731 fluorine Inorganic materials 0.000 title abstract 2
- 239000011737 fluorine Substances 0.000 title abstract 2
- -1 fluorine glycoside derivatives of pyrazoles Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 229930182470 glycoside Natural products 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125708 antidiabetic agent Drugs 0.000 abstract 1
- 229930182478 glucoside Natural products 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004028241A DE102004028241B4 (de) | 2004-06-11 | 2004-06-11 | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
PCT/EP2005/005959 WO2005121161A1 (de) | 2004-06-11 | 2005-06-03 | Neue fluorglykosidderivate von pyrazolen, diese verbindungen enthaltende arzneimittel und deren verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070176L true NO20070176L (no) | 2007-03-09 |
Family
ID=35355753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070176A NO20070176L (no) | 2004-06-11 | 2007-01-10 | Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav |
Country Status (34)
Country | Link |
---|---|
US (1) | US7820804B2 (es) |
EP (1) | EP1758914B1 (es) |
JP (1) | JP4996464B2 (es) |
CN (1) | CN100582116C (es) |
AR (1) | AR049393A1 (es) |
AU (1) | AU2005252329B2 (es) |
BR (1) | BRPI0510770A (es) |
CA (1) | CA2570042C (es) |
CR (1) | CR8773A (es) |
CY (1) | CY1107426T1 (es) |
DE (2) | DE102004028241B4 (es) |
DK (1) | DK1758914T3 (es) |
EC (1) | ECSP067054A (es) |
ES (1) | ES2296180T3 (es) |
HK (1) | HK1100411A1 (es) |
HR (1) | HRP20080023T3 (es) |
IL (1) | IL179757A (es) |
MA (1) | MA28653B1 (es) |
MX (1) | MXPA06013513A (es) |
MY (1) | MY143565A (es) |
NO (1) | NO20070176L (es) |
NZ (1) | NZ551948A (es) |
PE (1) | PE20060297A1 (es) |
PL (1) | PL1758914T3 (es) |
PT (1) | PT1758914E (es) |
RS (1) | RS50541B (es) |
RU (1) | RU2370499C2 (es) |
SI (1) | SI1758914T1 (es) |
TN (1) | TNSN06409A1 (es) |
TW (1) | TWI382030B (es) |
UA (1) | UA89787C2 (es) |
UY (1) | UY28955A1 (es) |
WO (1) | WO2005121161A1 (es) |
ZA (1) | ZA200608832B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2076503B1 (en) | 2006-05-19 | 2013-07-17 | Taisho Pharmaceutical Co., Ltd | C-phenyl glycitol compound for the treatment of diabetes |
EP2036901B1 (en) * | 2006-06-29 | 2013-05-01 | Taisho Pharmaceutical Co., Ltd | C-phenyl 1-thioglucitol compound |
CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
DE102006053637B4 (de) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
AU2007332476A1 (en) | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | 1-phenyl 1-thio-D-glucitol derivative |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP5272395B2 (ja) * | 2007-12-12 | 2013-08-28 | セントラル硝子株式会社 | 4−デオキシ−4−フルオロ−d−グルコース誘導体の製造方法 |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
MY155418A (en) * | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
KR101653853B1 (ko) | 2009-02-23 | 2016-09-02 | 다이쇼 세이야꾸 가부시끼가이샤 | Sglt1 저해제로서의 4-이소프로필페닐 글루시톨 화합물 |
EP2298782A1 (en) | 2009-08-26 | 2011-03-23 | Sanofi-Aventis | Method for producing pyrazole glycoside derivatives |
DK2470552T3 (en) * | 2009-08-26 | 2014-02-17 | Sanofi Sa | NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE |
JP2013506635A (ja) | 2009-10-02 | 2013-02-28 | サノフイ | 骨疾患を処置するための薬剤を製造するためのsglt−1/sglt−2阻害剤活性を有する化合物の使用 |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
EA021983B1 (ru) | 2009-11-02 | 2015-10-30 | Пфайзер Инк. | Производные диоксабицикло[3.2.1]октан-2,3,4-триола |
JP5798123B2 (ja) | 2009-11-13 | 2015-10-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 低質量のメトホルミン製剤 |
RU2583920C2 (ru) | 2009-11-13 | 2016-05-10 | Астразенека Аб | Композиция двухслойной таблетки |
MX2012005365A (es) | 2009-11-13 | 2012-05-29 | Bristol Myers Squibb Co | Formulaciones de tableta de liberacion inmediata. |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
JP5532138B2 (ja) | 2010-08-20 | 2014-06-25 | 大正製薬株式会社 | 4−イソプロピル−6−メトキシフェニルグルシトール化合物 |
RU2013112368A (ru) | 2010-08-20 | 2014-09-27 | Тайсо Фармасьютикал Ко., Лтд. | Кристаллическая форма 4-изопропилфенилглюцитольного соединения и способ ее получения |
EP2611442B1 (en) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
CA2826391C (en) | 2011-02-01 | 2017-01-24 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8614195B2 (en) * | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
AR087701A1 (es) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
UA113086C2 (xx) | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 | |
TW201425326A (zh) | 2012-10-05 | 2014-07-01 | Lilly Co Eli | 新穎脲化合物 |
KR102078433B1 (ko) | 2013-02-04 | 2020-02-17 | 다이쇼 세이야꾸 가부시끼가이샤 | 변비증의 예방 또는 치료약 |
EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
AR098670A1 (es) * | 2013-11-08 | 2016-06-08 | Lilly Co Eli | Inhibidor de sglt1 |
EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
MX2020010433A (es) * | 2018-04-04 | 2020-10-28 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT850948E (pt) * | 1996-12-26 | 2002-08-30 | Tanabe Seiyaku Co | Derivados propiofenona e processo para a preparacao dos mesmos |
DK1213296T3 (da) * | 1999-08-31 | 2004-08-16 | Kissei Pharmaceutical | Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
WO2002036602A1 (fr) * | 2000-11-02 | 2002-05-10 | Ajinomoto Co., Inc. | Nouveaux derives du pyrazole et remedes au diabete contenant ces derniers |
WO2002064839A2 (en) * | 2001-02-14 | 2002-08-22 | Tularik Inc. | Methods for the diagnosis and treatment of tumors employing the hepsin gene |
AU2003254847B2 (en) * | 2002-08-08 | 2009-06-04 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
WO2004019958A1 (ja) * | 2002-08-27 | 2004-03-11 | Kissei Pharmaceutical Co., Ltd. | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
AU2003272903A1 (en) * | 2002-10-04 | 2004-04-23 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
JPWO2004050122A1 (ja) * | 2002-12-04 | 2006-03-30 | キッセイ薬品工業株式会社 | 高血糖症に起因する疾患の予防又は治療剤 |
DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
EP1637539B1 (en) * | 2003-06-20 | 2012-01-18 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, drug composition containing the same and production intermediate therefor |
-
2004
- 2004-06-11 DE DE102004028241A patent/DE102004028241B4/de not_active Expired - Fee Related
-
2005
- 2005-06-03 DE DE502005002056T patent/DE502005002056D1/de active Active
- 2005-06-03 AU AU2005252329A patent/AU2005252329B2/en not_active Ceased
- 2005-06-03 SI SI200530142T patent/SI1758914T1/sl unknown
- 2005-06-03 PL PL05746637T patent/PL1758914T3/pl unknown
- 2005-06-03 BR BRPI0510770-9A patent/BRPI0510770A/pt not_active IP Right Cessation
- 2005-06-03 UA UAA200700259A patent/UA89787C2/ru unknown
- 2005-06-03 ES ES05746637T patent/ES2296180T3/es active Active
- 2005-06-03 MX MXPA06013513A patent/MXPA06013513A/es active IP Right Grant
- 2005-06-03 WO PCT/EP2005/005959 patent/WO2005121161A1/de active Application Filing
- 2005-06-03 EP EP05746637A patent/EP1758914B1/de active Active
- 2005-06-03 NZ NZ551948A patent/NZ551948A/en not_active IP Right Cessation
- 2005-06-03 RU RU2007101154/04A patent/RU2370499C2/ru not_active IP Right Cessation
- 2005-06-03 RS RSP-2008/0017A patent/RS50541B/sr unknown
- 2005-06-03 JP JP2007526254A patent/JP4996464B2/ja not_active Expired - Fee Related
- 2005-06-03 CA CA2570042A patent/CA2570042C/en not_active Expired - Fee Related
- 2005-06-03 DK DK05746637T patent/DK1758914T3/da active
- 2005-06-03 CN CN200580019067A patent/CN100582116C/zh not_active Expired - Fee Related
- 2005-06-03 PT PT05746637T patent/PT1758914E/pt unknown
- 2005-06-09 MY MYPI20052616A patent/MY143565A/en unknown
- 2005-06-09 TW TW094118973A patent/TWI382030B/zh not_active IP Right Cessation
- 2005-06-10 UY UY28955A patent/UY28955A1/es unknown
- 2005-06-10 PE PE2005000666A patent/PE20060297A1/es not_active Application Discontinuation
- 2005-06-13 AR ARP050102406A patent/AR049393A1/es not_active Application Discontinuation
-
2006
- 2006-10-24 ZA ZA200608832A patent/ZA200608832B/en unknown
- 2006-11-27 CR CR8773A patent/CR8773A/es not_active Application Discontinuation
- 2006-11-30 IL IL179757A patent/IL179757A/en not_active IP Right Cessation
- 2006-12-05 MA MA29515A patent/MA28653B1/fr unknown
- 2006-12-06 US US11/567,410 patent/US7820804B2/en not_active Expired - Fee Related
- 2006-12-08 EC EC2006007054A patent/ECSP067054A/es unknown
- 2006-12-08 TN TNP2006000409A patent/TNSN06409A1/en unknown
-
2007
- 2007-01-10 NO NO20070176A patent/NO20070176L/no not_active Application Discontinuation
- 2007-07-31 HK HK07108324.3A patent/HK1100411A1/xx not_active IP Right Cessation
-
2008
- 2008-01-16 HR HR20080023T patent/HRP20080023T3/xx unknown
- 2008-02-04 CY CY20081100139T patent/CY1107426T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070176L (no) | Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav | |
NO20091893L (no) | Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav. | |
NO20050649L (no) | Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse derav | |
NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
NO20085066L (no) | 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
NO20066055L (no) | Pyridinderivater | |
NO20082445L (no) | Neuropeptid-2 reseptor-agonister | |
NO20064166L (no) | Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter | |
NO20083863L (no) | Pyrazoler som 11-beta-hsd-1 | |
NO20085067L (no) | 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
NO20085064L (no) | 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
NO20051165L (no) | Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet | |
NO20060001L (no) | Nye P2X7-reseptorantagonister og deres anvendelse | |
WO2007036532A3 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
NO20060908L (no) | Substituerte tazol-benzoisotiazoldioksidderivater, deres fremstilling og anvendelse | |
NO20076460L (no) | Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav | |
NO20074391L (no) | CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter | |
NO20062491L (no) | Benzoksazinderivter og deres anvendelse | |
NO20061839L (no) | Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav | |
NO20076680L (no) | Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter | |
NO20060146L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
NO20060147L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
NO20065327L (no) | Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid. | |
NO20072389L (no) | Substituerte benzokinolizinderivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |